Moleculin Biotech Reports "Exceptionally Encouraging" Preliminary Efficacy Data for Annamycin in Pivotal AML Trial

summarizeSummary

Moleculin Biotech announced preliminary blinded efficacy data from its pivotal Phase 2B/3 MIRACLE study for Annamycin in R/R AML, reporting a 40% composite complete remission rate in the first 30 subjects, significantly outperforming historical controls.

check_boxKey Events

• Preliminary Efficacy Data Reported

  A preliminary blinded composite complete remission (CRc) rate of 40% was observed in the first 30 subjects treated in the pivotal Phase 2B/3 MIRACLE trial for Annamycin in relapsed/refractory Acute Myeloid Leukemia (AML).

• Strong Performance Against Historical Controls

  The 40% CRc rate, comprising 30% complete remission (CR) and 10% complete remission with partial hematological recovery (CRh), represents a 67% improvement over historical cytarabine response rates.

• Efficacy in Challenging Patient Population

  Approximately 35% of the subjects treated to date were relapsed or refractory from a venetoclax regimen, a patient population generally considered among the most challenging to treat.

• Pivotal Trial Progress and Unblinding Timeline

  35 subjects have been treated to date, with another 11 in screening or identified. The company is on track to treat the 45th subject in Q1 2026, with unblinding of efficacy data for these subjects expected in late Q2 2026.

auto_awesomeAnalysis

This 8-K provides a highly positive update on Moleculin Biotech's pivotal MIRACLE trial for Annamycin, a critical drug candidate for the company. The reported preliminary blinded efficacy data, showing a 40% composite complete remission rate, is exceptionally strong, especially when compared to historical outcomes for standard treatments and considering the challenging patient population, including those who failed venetoclax regimens. This data significantly de-risks Annamycin's clinical development and reinforces its potential as a "significant advancement" in treating relapsed/refractory AML. The confirmation of the drug's non-cardiotoxic profile further enhances its competitive position. Investors should monitor the upcoming unblinding of efficacy data for the first 45 subjects in late Q2 2026, as this will be a major value inflection point.